Retraso del crecimiento

Arabinogalactan (specifically larch arabinogalactan) is identified as a prebiotic fiber relevant to diverticulitis management that nourishes beneficial bacteria and supports the gut immune system. Authoritative integrative medicine resources for diverticulitis specifically endorse arabinogalactan as a prebiotic fiber supporting microbiome health in the context of diverticular disease.

Beta-glucan is a soluble dietary fiber with documented effects on gut microbiota modulation, mucosal immunity, and colonic transit relevant to diverticular disease. As a soluble fermentable fiber, it contributes to SCFA production and microbiome health, and is positioned within the broader high-fiber dietary approach recommended across multiple diverticular disease guidelines.

Bifidobacterium species are among the probiotic genera most studied in diverticular disease, often used in multi-strain formulations. A 2025 systematic review and meta-analysis (13 RCTs) found probiotic therapy—commonly including Bifidobacterium strains—significantly improved abdominal pain (SMD 0.63) and reduced recurrence risk (RR 0.22) in diverticular disease. Multi-strain formulations with Bifidobacterium combined with Lactobacillus showed the most consistent benefits.

Bifidobacterium breve is a component of the VSL#3 multi-strain probiotic tested in diverticular disease remission trials. As part of multi-strain formulations, B. breve-containing probiotics have demonstrated symptom control in diverticular disease over 12-month studies.

Bifidobacterium infantis is a component of the VSL#3 multi-strain probiotic studied in diverticular disease remission trials. As part of multi-strain formulations, B. infantis-containing probiotics have demonstrated maintained remission in diverticular disease over 12-month RCTs.

Bifidobacterium longum is a specific strain included in the VSL#3 probiotic formulation studied in 12-month RCTs in diverticular disease remission. Multi-strain formulations containing B. longum have been associated with maintained symptom relief in diverticular disease, and the broader evidence from a 2025 meta-analysis supports the role of Bifidobacterium-containing multi-strain probiotics in reducing diverticular disease pain and recurrence.

Boswellia serrata was specifically combined with curcumin in a 30-day clinical study in SUDD patients demonstrating significant gastric pain reduction. Multiple authoritative diverticulitis management resources identify Boswellia for its gastrointestinal anti-inflammatory properties via 5-lipoxygenase inhibition, making it mechanistically well-suited for diverticular inflammation.

Boswellia serrata extract (Boswellic Acid) was combined with curcumin in a 30-day clinical study in SUDD patients, demonstrating significant reduction in gastric pain. Boswellia is noted for anti-inflammatory properties in gastrointestinal conditions, and multiple authoritative diverticular disease protocols identify it as a potentially beneficial natural anti-inflammatory compound.

Butyrate-producing probiotics (Clostridium butyricum) have been studied in symptomatic uncomplicated diverticular disease (SUDD). Evidence suggests butyrate may reduce chronic mucosal inflammation and symptom burden in diverticular patients through microbiome and barrier modulation.

Curcumin has been specifically studied as a natural anti-inflammatory agent in diverticular disease. A 30-day longitudinal study of a curcumin-Boswellia phytosome formulation in SUDD patients demonstrated significant reduction in gastric pain. Animal models show curcumin reduces TNF-α, an inflammatory cytokine directly implicated in diverticular disease and acute diverticulitis.

DHA is co-recommended alongside EPA by authoritative diverticular disease protocols as an anti-inflammatory omega-3 fatty acid. Fish oil containing both EPA and DHA is specifically recommended by multiple evidence-based diverticulitis management resources at 1,000–2,000 mg/day to address the inflammatory component of diverticular disease.

EPA is an omega-3 fatty acid recommended by multiple university-associated medical centers and evidence-based resources for diverticular disease due to its anti-inflammatory properties. Several authoritative protocols suggest EPA (from fish oil) at 1,000 mg one to two times per day for diverticulitis patients, and low omega-3 levels have been noted in patients with inflammatory bowel conditions overlapping with diverticular pathophysiology.

Fish oil (as a source of EPA and DHA) is specifically recommended by authoritative medical evidence-based resources for diverticulitis at 1,000 mg one to two times per day. Multiple university-associated medical center protocols and evidence-based databases endorse fish oil supplementation for its anti-inflammatory activity in diverticular disease.

Fructooligosaccharides (FOS) are soluble prebiotic fibers that selectively stimulate beneficial gut bacteria relevant to diverticular disease. They are fermented to short-chain fatty acids including butyrate, supporting colonocyte health and reducing mucosal inflammation, and are positioned within the broader fiber and prebiotic approach to diverticular disease management supported by gastroenterological guidelines.

Glucomannan (konjac fiber) is a highly viscous soluble dietary fiber positioned within the high-fiber dietary approach recommended for diverticular disease by major gastroenterological guidelines. As a bulk-forming and fermentable fiber, it reduces intraluminal colonic pressure, promotes beneficial microbiota, and contributes to SCFA production supporting colonocyte health.

Inulin is a soluble prebiotic fiber that feeds beneficial gut bacteria and may be relevant to diverticular disease management through its prebiotic action supporting Bifidobacterium and Lactobacillus species. It is fermented to short-chain fatty acids including butyrate, supporting colonocyte health and reducing mucosal inflammation in the colon.

L-glutamine is identified in multiple evidence-based diverticulitis management resources as an important intestinal mucosal supportive agent. It is the primary energy substrate for intestinal epithelial cells, and has been studied for preserving structural and functional intestinal health during and after injury. While direct diverticulitis RCT evidence is absent, authoritative sources recommend it for overall intestinal health support in the context of diverticular disease.

Lactobacillus species are the most studied probiotic genus in diverticular disease, with multiple RCTs demonstrating symptom improvement and recurrence reduction. Combined Lactobacillus-based probiotics significantly reduced abdominal pain and, in two RCTs, reduced recurrence risk by approximately 78%. Specific strains studied include L. reuteri, L. paracasei, L. casei, and L. plantarum.

Lactobacillus acidophilus is one of the specific Lactobacillus strains identified by authoritative clinical guidance for use in diverticular disease. It has been included in multi-strain probiotic formulations (e.g., VSL#3) studied in RCTs showing benefit in diverticular disease symptom management and remission maintenance.

Lactobacillus bulgaricus is a component of the VSL#3 multi-strain probiotic formulation that has been studied in diverticular disease remission maintenance trials. As part of this clinically evaluated combination, L. bulgaricus-containing probiotics have shown benefit in diverticular disease management.

Lactobacillus casei is one of the best-studied specific probiotic strains in diverticular disease, featured in multiple dedicated RCTs. Two Tursi et al. prospective randomized open-label studies demonstrated that L. casei reduced recurrence of symptomatic uncomplicated diverticular disease and was most effective when combined with mesalazine for long-term remission maintenance up to 24 months.

Lactobacillus paracasei is specifically supported by dedicated RCTs in diverticular disease. A 2025 post-hoc analysis of a 12-month, double-blind, placebo-controlled RCT found L. paracasei CNCM I-1572 significantly better than placebo in preventing the first episode of acute diverticulitis in SUDD patients. An earlier 50-patient RCT showed L. paracasei F19 plus high-fiber diet was significantly superior to high-fiber diet alone for reducing abdominal pain and bloating.

Lactobacillus plantarum is a component of the VSL#3 multi-strain probiotic formulation evaluated in diverticular disease remission trials, and has been identified as an evidence-supported strain for diverticular disease in the published literature. It is noted for strengthening intestinal epithelial barrier function and modulating gut microbiota relevant to diverticular inflammation.

Lactobacillus reuteri has the most direct strain-specific RCT evidence for acute uncomplicated diverticulitis. A double-blind, placebo-controlled RCT (Petruzziello et al., 2019; n=109) demonstrated that L. reuteri ATCC PTA 4659 supplementation significantly reduced inflammatory markers and improved clinical outcomes in acute uncomplicated diverticulitis patients. A Phase 3 clinical trial also investigated L. reuteri DSM 17938 in non-complicated diverticular disease.

Lactobacillus rhamnosus is among the most extensively studied probiotic strains globally, with established evidence for immune modulation and gut microbiota diversity maintenance. It is identified as a contributing strain in multi-strain probiotic formulations showing benefit in diverticular disease, and is specifically referenced in diverticulitis probiotic evidence summaries.

Omega-3 fatty acids (found in fish oil) are specifically recommended by multiple authoritative medical resources for diverticulitis due to their anti-inflammatory properties. The Atlantic Health/ADAM evidence-based resource recommends 1,000 mg fish oil one to two times daily for diverticulitis, and Life Extension's diverticular disease protocol identifies omega-3s as relevant natural anti-inflammatory agents given the overlap between diverticular disease inflammation and IBD.

A prospective cohort study involving over 50,000 women (Nurses' Health Study) found that specific fruits including apples/pears were associated with reduced risk of diverticulitis. Higher fruit fiber intake was associated with a 14% lower risk of diverticulitis. Pear's sorbitol and pectin soften stool and reduce colonic pressure, the primary mechanical driver of diverticular formation.

Psyllium (Plantago ovata) fiber reduces luminal pressure in the colon, which is associated with lower risk of diverticulosis development and symptom reduction. Multiple reviews recognize regular psyllium use as minimizing the risk of diverticulosis and its complications.

Psyllium is a soluble fiber supplement specifically recommended by multiple gastroenterological guidelines for diverticular disease management. It adds bulk to stool, reduces intraluminal colonic pressure, and promotes regular bowel movements. A 12-week clinical trial demonstrated normalization of intestinal motility and reduction of pain and flatulence in uncomplicated diverticular disease patients. UCSF and American Gastroenterological Association guidelines conditionally recommend psyllium fiber supplementation after acute diverticulitis resolves.

Quercetin is a polyphenol with antioxidant and anti-inflammatory properties identified in recent evidence reviews as potentially beneficial in diverticular disease. A 2025 narrative review specifically addressing polyphenols in diverticular disease highlighted quercetin among key compounds that may protect intestinal integrity, modulate gut microbiota, and reduce oxidative stress characteristic of diverticular disease pathophysiology.

Resveratrol is identified in the 2025 narrative review on polyphenols in diverticular disease as a relevant bioactive compound offering antioxidant and anti-inflammatory protection potentially applicable to SUDD management. It inhibits NF-κB, reduces IBD-associated mucosal inflammation in animal models, and addresses the oxidative stress pathophysiology now recognized as central to diverticular disease progression.

Saccharomyces boulardii is specifically listed by Atlantic Health's evidence-based complementary medicine resource for diverticulitis as a probiotic to help maintain intestinal health. It is a non-pathogenic yeast probiotic widely studied for gastrointestinal inflammation and dysbiosis, both central to diverticular disease pathophysiology.

Streptococcus thermophilus is a component of the VSL#3 multi-strain probiotic formulation studied in diverticular disease remission maintenance, and is noted for producing anti-inflammatory metabolites and enhancing gut microbiota balance in gastrointestinal disease contexts.

Turmeric (containing curcumin as its primary bioactive) was studied in a combined curcumin-Boswellia formulation clinical trial in SUDD patients, demonstrating significant pain reduction at 30 days. Curcumin inhibits TNF-α, an inflammatory cytokine directly associated with diverticular disease, and multiple diverticular disease protocols identify turmeric/curcumin as a relevant natural anti-inflammatory agent.

Aloe vera has a long traditional use in gastrointestinal inflammation and irritation. Authoritative integrative medicine resources for diverticulitis specifically identify aloe vera as a botanical agent that 'can help soothe and calm inflamed tissues' in the context of diverticulitis management. Its mucilaginous gel has been used traditionally to coat and protect gastrointestinal mucosa.

Cat's claw is listed as a traditional remedy for diverticulitis in multiple herbalism and integrative medicine sources, including RxList, which describes its use for 'swelling and pain (inflammation) of the large intestine (diverticulitis).' No clinical trials for diverticulitis have been conducted.

Flaxseed's high fiber content is mechanistically relevant to diverticular health, as dietary fiber reduces intraluminal pressure and constipation, the primary contributors to diverticulosis development. Traditional use and fiber pharmacology support this, though dedicated flaxseed RCTs in diverticular disease are lacking.

High dietary fiber intake including from oats is traditionally recommended to prevent diverticular disease and manage diverticular health. Epidemiological evidence supports fiber's role in diverticular prevention, though oat-specific RCTs in diverticulitis are lacking.

Slippery elm is listed in multiple pharmacopoeial and herbal reference sources as used for diverticulitis, with a mechanism based on reflex mucus stimulation and mucosal coating. No human clinical trials address this indication specifically.

Slippery elm is traditionally listed in herbal and integrative references for diverticulitis. RxList and Herbal Reality both cite diverticulitis among its traditional indications. The mucilage is proposed to soothe inflamed diverticula and support bowel regularity. No clinical trials specifically for diverticulitis have been identified.

Wild yam is documented in multiple herbal traditions as a treatment for diverticulitis and intestinal inflammation, attributed to its antispasmodic and anti-inflammatory properties. Herbal Reality, the Naturopathic Herbalist monograph, and other herbal medicine references cite this use. No clinical trial evidence exists.